BIO INX
Develops and commercializes high-quality bioinks and biomaterials for 3D bioprinting applications in tissue engineering and regenerative medicine.
- CEO / Founder
- Jasper Van Hoorick
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $2.5M
- Latest Round
- Grant
- Key Investors
- Flanders Innovation & Entrepreneurship (VLAIO); imec.xpand; QBIC; Ghent University; KU Leuven
Technology & Products
Key Products
Hydrobio INX U200 resin; DEGRES INX biodegradable resin; Custom bioink formulations; Inks for Multiphoton Lithography; Inks for Deposition-based 3D Printing; Inks for Digital Light Processing & Stereolithography
Technological Advantage
Proprietary bioink formulations with tunable mechanical and biological properties, validated through academic research and partnerships with bioprinter manufacturers.
Differentiation
Value Proposition
Provides standardized, high-performance bioinks that reduce research time and enable reproducible bioprinting outcomes, accelerating development of tissue engineering solutions.
How They Differentiate
Focuses exclusively on bioink materials rather than bioprinters, with deep academic roots in polymer chemistry enabling customized formulations for specific applications.
Market & Competition
Target Customers
Researchers, clinicians, biotech companies, and academic institutions
Industry Verticals
Medical; Biotechnology; Research
Competitors
Cellink; Allevi; Organovo
Growth & Milestones
Growth Metrics
Secured €240,000 grant for bone and cartilage repair project in 2024; established four distribution partnerships with bioprinter manufacturers.
Major Milestones
Incorporated as BIO INX in April 2022; Launched Hydrobio INX U200 resin in 2021; Secured €240,000 grant in 2024; Established partnerships with FELIXprinters, Regemat 3D, UpNano, and Nanoscribe